Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Safety and Efficacy Study of AGN-193408 SR in Open-Angle Glaucoma or Ocular Hypertension
jRCT2031220053Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2022
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of AGN-193408 SR in open-angle glaucoma (OAG) and ocular hypertension (3 arms), sponsored by AbbVie Inc. Primary endpoints: Change from Baseline in Time-Matched Intraocular Pressure (IOP) in the Study Eye and Number of participants experiencing treatment Time to Rescue Treatment or Re-Treatment in the Study Eye. Started Dec 2022; status: active, not recruiting.
02
Drugs
AGN-193408 SR
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCT2031220053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220053.